Pricking blood therapy for chronic urticaria: a randomized controlled trial

Phase 1

• Conditions: Chronic Urticaria

• Registration Number: ITMCTR2100005233
• Lead Sponsor: Hebei University of Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Those who meet the diagnostic criteria of chronic urticaria in the EAACI/GA2LEN/EDF/WAO guidelines for the treatment of urticaria (2017) and the Chinese guidelines for the treatment of urticaria (2018);
2. Aged 18-70 years;
3. No antihistamines use within 2 weeks before enrollment and no steroids or immunosuppressive drugs within 1 month;
4. The liver and kidney functions are normal;
5. Not participating in other ongoing clinical studies;
6. Voluntary participation and signed informed consent form.

Exclusion Criteria

1. Unconscious people who cannot express subjective symptoms of discomfort and psychiatric patients;
2. Those with Progressive malignant tumors or other serious wasting diseases, who are prone to co-infection and bleeding;
3. Patients with severe primary diseases such as cardiovascular, liver, kidney, digestion, hematopoietic system;
4. Pregnant and lactating women.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rticaria activity score (UAS);

Secondary Outcome Measures

Name	Time	Method
Visual analogue scale (VAS);Dermatology Life Quality Index (DLQI);